Evidence map›Paper›PMID 28144153›Full record

ArticleOncoTargets and therapy2017

Fubin Li, Yiping Li, Kewei Zhang, Ye Li, Ping He, Yujia Liu, Hongyan Yuan, Honghua Lu, Jinxiang Liu, Songtian Che and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Genetic secrets of long-term glioblastoma survivors.Bosnian journal of basic medical sciences · 2019
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Fubin LiDepartment of Neurosurgery of the First Clinical Hospital.
Yiping LiDepartment of Neurosurgery of the First Clinical Hospital.
Kewei ZhangDepartment of Neurosurgery of the First Clinical Hospital.
Ye LiDepartment of Neurosurgery of the First Clinical Hospital.
Ping HeDepartment of Neurosurgery of the First Clinical Hospital.
Yujia LiuDepartment of Neurosurgery of the First Clinical Hospital.
Hongyan YuanDepartment of Immunology, Norman Bethune College of Medicine.
Honghua LuDepartment of Neurosurgery of the First Clinical Hospital.
Jinxiang LiuDepartment of Neurosurgery of the First Clinical Hospital.
Songtian CheDepartment of Neurosurgery of the Second Clinical Hospital.
Zhenju LiDepartment of Neurosurgery of the Fourth Clinical Hospital, Jilin University, Changchun, People's Republic of China.
Li BieDepartment of Neurosurgery of the First Clinical Hospital; Department of Pathology and Laboratory Medicine, School of Medicine, University of California - Irvine, Irvine, CA, USA.
Jilin University · CNFirst Hospital of Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is the most common malignant and lethal type of primary central nervous system tumor in humans. In spite of its high lethality, a small percentage of patients have a relatively good prognosis, with median survival times of 36 months or longer. The identification of clinical subsets of GBM associated with distinct molecular genetic profiles has made it possible to design therapies tailored to treat individual patients.

methodsWe compared microarray data sets from long-term survivors (LTSs) and short-term survivors (STSs) to screen for prognostic biomarkers in GBM patients using the WebArrayDB platform. We focused on

resultsExpression levels of the mRNAs of these 3 genes were higher in the GBM samples than in normal brain samples and these 3 genes were significantly upregulated in STSs compared to the levels in LTS samples (

conclusionTo our knowledge, this is the first report describing

Indexed as

FBLN4glioblastomaIGFBP-2prognosistumor marker

Identifiers

PMID28144153
PMCPMC5248947
OpenAlexW2574587928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.